logo-loader
viewOptiBiotix Health PLC

OptiBiotix to target blood pressure market through licensing deal with Nutrilinea

Hypertension is a global healthcare issue and is one of the strongest risk factors for almost all cardiovascular diseases.

Nurse performing blood pressure test
Hypertension is often referred to as a 'silent killer' as it has no obvious symptoms

Life sciences business OptiBiotix Health PLC (LON:OPTI) has signed a licence agreement with Nutrilinea, an Italian manufacturer of food supplement formulations.

Under the terms of the agreement, Nutrilenea has been given the rights to use OptiBiotix’s cholesterol and blood pressure-reducing LPLDL product in a food supplement for the reduction of high blood pressure (hypertension).

READ OptiBiotix Health enters precision nutrition field with Spanish LPLDL licensing deal

Nutrilinea will cover the cost of all product development, manufacturing and human studies in return for 12 months exclusivity for the European market, excluding the UK - ProBiotix has exclusivity for the UK and all other markets outside Europe.

Nutrilinea currently produces the OptiBiotix’s CholBiome, CholBiomex3 and SlimBiome Medical products and has technology that enables the production of multilayer tablets used in CholBiomex3 that will also be used for this new product.

"We are delighted to announce this deal with Nutrilinea who are covering the cost of product development, manufacturing and human studies, for a food supplement to reduce blood pressure,” said Dr Luis Gosalbez, the business development director at OptiBiotix.

“This broadens the use of LPLDL beyond cholesterol reduction and creates new market opportunities in the field of cardiovascular health. Hypertension is a global health issue which is on the rise where there are very few active ingredients or supplements proven to lower blood pressure in humans. The development of a hypertension product containing LPLDL has the potential to address a large global market of unmet clinical need," he added.

Quick facts: OptiBiotix Health PLC

Price: 65.5 GBX

AIM:OPTI
Market: AIM
Market Cap: £55.96 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of OptiBiotix Health PLC named herein, including the promotion by the Company of OptiBiotix Health PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: European healthcare broker sets 97p price target for...

OptiBiotix Health PLC's (LON:OPTI) Stephen O'Hara speaks to Proactive London following a research note whcih has been published on the company by Goetz partners - which has set OPTI a price target of 97p. O'Hara says Goetz partners are a leading European Investment Bank and broking firm and...

on 11/9/19

2 min read